Literature DB >> 17493042

Structural principles of tau and the paired helical filaments of Alzheimer's disease.

Eckhard Mandelkow1, Martin von Bergen, Jacek Biernat, Eva-Maria Mandelkow.   

Abstract

Tau, a major microtubule-associated protein in brain, forms abnormal fibers in Alzheimer's disease and several other neurodegenerative diseases. Tau is highly soluble and adopts a natively unfolded structure in solution. In the paired helical filaments of Alzheimer's disease, small segments of tau adopt a beta-conformation and interact with other tau molecules. In the filament core, the microtubule-binding repeat region of tau has a cross-beta structure, while the rest of the protein retains its largely unfolded structure and gives rise to the fuzzy coat of the filaments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17493042     DOI: 10.1111/j.1750-3639.2007.00053.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  66 in total

1.  [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].

Authors:  A Schneider; P Falkai; A Papassotiropoulos
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

Review 2.  Amyloid structure and assembly: insights from scanning transmission electron microscopy.

Authors:  Claire Goldsbury; Ulrich Baxa; Martha N Simon; Alasdair C Steven; Andreas Engel; Joseph S Wall; Ueli Aebi; Shirley A Müller
Journal:  J Struct Biol       Date:  2010-09-22       Impact factor: 2.867

Review 3.  Human fetal tau protein isoform: possibilities for Alzheimer's disease treatment.

Authors:  Nataša Jovanov-Milošević; Davor Petrović; Goran Sedmak; Mario Vukšić; Patrick R Hof; Goran Simić
Journal:  Int J Biochem Cell Biol       Date:  2012-05-15       Impact factor: 5.085

4.  Truncation of tau at E391 promotes early pathologic changes in transgenic mice.

Authors:  Pamela J McMillan; Brian C Kraemer; Linda Robinson; James B Leverenz; Murray Raskind; Gerard Schellenberg
Journal:  J Neuropathol Exp Neurol       Date:  2011-11       Impact factor: 3.685

5.  Recent advances in the development of immunotherapies for tauopathies.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  Exp Neurol       Date:  2010-10-21       Impact factor: 5.330

Review 6.  The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.

Authors:  Konstanze F Winklhofer; Jörg Tatzelt; Christian Haass
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

7.  Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.

Authors:  Patrick Reilly; Charisse N Winston; Kelsey R Baron; Margarita Trejo; Edward M Rockenstein; Johnny C Akers; Najla Kfoury; Marc Diamond; Eliezer Masliah; Robert A Rissman; Shauna H Yuan
Journal:  Neurobiol Dis       Date:  2017-06-10       Impact factor: 5.996

8.  Competing interactions stabilize pro- and anti-aggregant conformations of human Tau.

Authors:  Susanne Wegmann; Jonas Schöler; Christian A Bippes; Eckhard Mandelkow; Daniel J Muller
Journal:  J Biol Chem       Date:  2011-04-15       Impact factor: 5.157

Review 9.  Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.

Authors:  Yoshinari Miyata; John Koren; Janine Kiray; Chad A Dickey; Jason E Gestwicki
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 10.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.